Department of Emergency and General Internal Medicine, Fujita Health University School of Medicine, Toyoake, Aichi, Japan.
Division of Pulmonary, Allergy and Critical Care Medicine, University of Pittsburgh Medical Center and University of Pittsburgh School of Medicine, Pennsylvania, United States of America.
Clin Infect Dis. 2020 Jul 27;71(3):499-513. doi: 10.1093/cid/ciz876.
The clinical role of sputum Gram stain (SGS) in community-acquired pneumonia (CAP) diagnosis remains controversial. A 1996 meta-analysis of the diagnostic accuracy of SGS reported heterogeneous results. To update the available evidence, we performed a systematic review and a Bayesian standard and latent-class model meta-analysis.
We searched Medline, Embase, and Cochrane Central by 23 August 2018 to identify studies reporting on the diagnostic accuracy, yield (percentage of patients with any pathogen[s] correctly identified by SGS), and clinical outcomes of SGS in adult patients with CAP. Two reviewers extracted the data. We quantitatively synthesized the diagnostic accuracy and yield, and descriptively analyzed other outcomes.
Twenty-four studies with 4533 patients were included. The methodological and reporting quality of the included studies was limited. When good-quality sputum specimens were selected, SGS had a summary sensitivity of 0.69 (95% credible interval [CrI], .56-.80) and specificity of 0.91 (CrI, .83-.96) for detecting Streptococcus pneumoniae, and a sensitivity of 0.76 (CrI, .60-.87) and specificity of 0.97 (CrI, .91-.99) for Haemophilus influenzae. Adjusted analyses accounting for imperfect reference standards provided higher-specificity estimates than the unadjusted analyses. Bacterial pathogens were identified in 73% (CrI, 26%-96%) of good-quality specimens, and 36% (CrI, 22%-53%) of all specimens regardless of quality. Evidence on other bacteria was sparse.
SGS was highly specific to diagnose S. pneumoniae and H. influenzae infections in patients with CAP. With good-quality specimens, SGS can provide clinically actionable information for pathogen-directed antibiotic therapies.
痰革兰氏染色(SGS)在社区获得性肺炎(CAP)诊断中的临床作用仍存在争议。1996 年对 SGS 诊断准确性的荟萃分析报告结果存在异质性。为了更新现有证据,我们进行了系统评价和贝叶斯标准和潜在类别模型荟萃分析。
我们于 2018 年 8 月 23 日通过 Medline、Embase 和 Cochrane Central 检索了报道 SGS 对成人 CAP 患者诊断准确性、检出率(通过 SGS 正确识别任何病原体的患者百分比)和临床结局的研究。两名评审员提取数据。我们对诊断准确性和检出率进行了定量综合,对其他结局进行了描述性分析。
纳入了 24 项研究,共计 4533 例患者。纳入研究的方法学和报告质量有限。当选择高质量的痰标本时,SGS 检测肺炎链球菌的汇总敏感度为 0.69(95%可信区间[CrI],0.56-0.80)和特异性为 0.91(CrI,0.83-0.96),检测流感嗜血杆菌的敏感度为 0.76(CrI,0.60-0.87)和特异性为 0.97(CrI,0.91-0.99)。考虑到不完美的参考标准的调整分析提供了比未调整分析更高的特异性估计。在高质量标本中,73%(CrI,26%-96%)可鉴定出细菌病原体,而无论标本质量如何,36%(CrI,22%-53%)均可鉴定出细菌病原体。关于其他细菌的证据很少。
SGS 对诊断 CAP 患者的肺炎链球菌和流感嗜血杆菌感染具有高度特异性。在高质量标本的情况下,SGS 可为针对病原体的抗生素治疗提供临床可行的信息。